Related Experiment Videos
Antiepileptic effects of clobazam in children
Insights
Clobazam demonstrated antiepileptic effects in children with intractable epilepsy. While some achieved complete seizure freedom, others experienced partial improvement or no change, with mild side effects observed.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Benzodiazepines are commonly used as anticonvulsants, often featuring nitrogen radicals at specific molecular positions.
- Clobazam, a benzodiazepine derivative, possesses a distinct nitrogen radical configuration at positions 1 and 5.
- Intractable epilepsies in childhood represent a significant therapeutic challenge requiring novel treatment strategies.
Observation:
- This study investigated the efficacy of clobazam in 36 pediatric patients diagnosed with intractable epilepsy.
- Patients' ages ranged from 1 year 1 month to 16 years 5 months, with a mean age of 8 years.
- Dosing commenced at a mean of 0.33 mg/kg daily, escalating to 0.71 mg/kg based on individual response.
Findings:
- Nine patients (2 primary generalized, 7 secondary generalized epilepsy) achieved complete seizure remission.
- An additional nine patients (8 secondary generalized, 1 partial epilepsy) exhibited a ≥50% reduction in seizure frequency.
- Seizure frequency remained unchanged in 16 patients and increased in 2 (secondary generalized epilepsy). Antiepileptic effects were noted within 1-10 days of treatment initiation.
- Recurrences were observed in 4 of the 9 seizure-free patients within 1 to 10 months.
- Mean serum clobazam levels were 73 ng/ml in responders and 94 ng/ml in non-responders.
- Mild, transient side effects like drowsiness occurred in 17 patients, with no significant laboratory abnormalities detected.
Implications:
- Clobazam shows promise as an adjunctive therapy for specific pediatric epilepsy syndromes, particularly secondary generalized epilepsy.
- The observed variability in response and potential for seizure recurrence highlight the need for personalized treatment approaches and monitoring.
- Further research is warranted to elucidate the pharmacokinetic and pharmacodynamic factors influencing clobazam's efficacy and to optimize its use in pediatric epilepsy management.
Abstract:
Many benzodiazepines used as anticonvulsants have nitrogen radicals in positions 1 and 4. Clobazam has nitrogen radicals in positions 1 and 5. We studied the antiepileptic effect of clobazam in 36 patients with intractable epilepsies in childhood. Their ages were 1 year 1 month to 16 years 5 months (mean 8 years). The mean initial dose was 0.33 mg/kg of daily doses and increased up to 0.71 mg/kg. Nine cases (primary generalized epilepsy 2/2, secondary generalized epilepsy 7/29) were completely free from seizures, and another 9 (secondary generalized epilepsy 8/29, partial epilepsy 1/5) experienced a decrease of 50% or more in seizure frequency. Seizure frequency did not change in 16, and increased in the other 2 (secondary generalized epilepsy 2/29). The antiepileptic effects were observed on the first day to 10th day after clobazam treatment. There were recurrences of seizures in 4 out of 9 patients with complete control of seizures, 1 month alter in 3 and 10 months later in one. Mean serum clobazam level of 7 improved cases was 73 ng/ml and that of 3 cases with no response was 94 ng/ml. Although mild clinical side effects such as drowsiness were observed transiently in 17 cases, no abnormality was found in laboratory investigations performed.